看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
/ M: i& L0 i) \2 A3 h
5 A) ?& o" y7 a
. x8 p% G1 M* v2 O0 SCurrently available feasibility data for possible combination strategies.
( X9 c8 r6 U- Z————————————————————————————————
1 t. e/ t* z/ _: B& }Combination Feasibility according to preliminary data ; F: Z. P2 w9 a8 E; V5 }
——————————————————————————————————8 Z) o7 o. t& J# d$ B: {
Bevacizumab + sorafenib Yes, reduced dose 2 h; C& U+ G0 E- w& o5 |
Bevacizumab + sunitinib† No
* p$ Q6 T2 c5 CBevacizumab + temsirolimus Yes
8 ^3 H$ s$ [" Y8 ?8 z# w) a5 y. SBevacizumab + everolimus Yes
6 a2 G' {! j2 i4 A" s- s% [& kSorafenib + sunitinib ? 5 Z# D. `6 D7 T4 w0 ]
Sorafenib + temsirolimus Yes, reduced dose / T; T* {- o& W i4 {9 N9 w
Sorafenib + everolimus Yes, reduced dose
+ x* V: u& Z2 D* p$ _Sunitinib + temsirolimus† No 3 l! w6 R$ \" x; ]7 v
Sunitinib + everolimus ?
$ F; Y: W( l( z; f- V$ v VTemsirolimus + everolimus ?
" l: V0 i! n5 W. O) k. r& D————————————————————3 D7 R# O* R) j+ b; U+ h5 m6 }, T
†Led to US FDA warning.( F0 [4 F' h2 [) U
?: As yet unattempted combination.
. M1 p+ \1 i, R6 V1 w& j |